➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Harvard Business School
Express Scripts
Moodys
AstraZeneca

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 9,149,532


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 9,149,532 protect, and when does it expire?

Patent 9,149,532 protects SAVAYSA and is included in one NDA.

This patent has forty-one patent family members in twenty-eight countries.

Summary for Patent: 9,149,532
Title:Pharmaceutical composition
Abstract: To provide pharmaceutical preparation exhibiting satisfactory dissolution property in a wide pH range. The pharmaceutical composition is characterized by containing (A) N.sup.1-(5-chloropyridin-2-yl)-N.sup.2-((1S,2R,4S)-4-[(dimethylamino)carb- onyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl- ]amino}cyclohexyl)ethanediamide, represented by the following formula (1), a pharmacologically acceptable salt thereof, or a hydrate of any of these, and (B) one or more species selected from the group consisting of a sugar alcohol and a water-swelling additive. ##STR00001##
Inventor(s): Kojima; Masazumi (Shinagawa-ku, JP), Kuno; Yoshio (Shinagawa-ku, JP), Nakagami; Hiroaki (Shinagawa-ku, JP), Sagasaki; Shinji (Shimada, JP), Ishidoh; Koichi (Hiratsuka, JP), Sekiguchi; Gaku (Hiratsuka, JP)
Assignee: Daiichi Sanykyo Company, Limited (Tokyo, JP)
Application Number:13/968,776
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Formulation;

Drugs Protected by US Patent 9,149,532

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-001 Jan 8, 2015 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-002 Jan 8, 2015 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Daiichi Sankyo Inc SAVAYSA edoxaban tosylate TABLET;ORAL 206316-003 Jan 8, 2015 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,149,532

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2007-087327Mar 29, 2007

International Family Members for US Patent 9,149,532

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2008241982 ⤷  Free Forever Trial
Brazil PI0809205 ⤷  Free Forever Trial
Canada 2680039 ⤷  Free Forever Trial
China 101652139 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Express Scripts
McKinsey
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.